Monitoring program flags cancer patients at risk of highly toxic chemotherapy side effects

Testing for this genetic variant can help oncologists, patients alter treatment to avoid life-threatening toxicity

5:00 AM

Author | Nicole Fawcett

IV drip
Getty Images

A routine blood test can determine when a genetic anomaly puts someone at high risk of dangerously toxic side effects from a common chemotherapy.

But with no clinical guidelines or requirements to test for the gene, uptake has been limited.

Researchers from the University of Michigan Health Rogel Cancer Center have developed a monitoring system using a research genetics program to trigger alerts about cancer patients suspected to have the DPYD gene variant.

They hope that alerting oncologists to patients at risk could lead to more testing.

“Pharmacogenetics can help inform clinical treatment decisions. In the case of DPYD testing, it can be lifesaving,” said study author Daniel L. Hertz, Pharm.D., Ph.D., associate professor of pharmacy at the University of Michigan College of Pharmacy.

“Unfortunately, the U.S. Food and Drug Administration does not recommend routine testing, which creates a barrier for oncologists to adopt this practice. We wanted to create a strategy to make it easier.”

Fluoropyrimidine-based chemotherapies, which include 5-fluorouracil and capecitabine, are metabolized by an enzyme encoded by the DPYD gene.

About 6% of people have a genetic variant in DPYD that makes them metabolize fluoropyrimidine more slowly, which can lead to severe and fatal toxicity.

It’s a small number but the impact is serious: more than half experience severe toxicity and about 2% die.

SEE ALSO: Circulating biomarkers, a new frontier in cancer care, brings both hope and unease to the clinic

Testing for variants in this gene can identify patients who are at this unacceptably high risk of severe, life-threatening toxicity from these drugs.

Oncologists can then begin treatment at lower doses to limit side effects or opt for another drug. Testing involves a blood sample submitted to a clinical lab. Results are returned within several days. Cost is $250-$500, which may be paid by insurance.

Researchers tapped into the Michigan Genomics Initiative, a research genetic database at the University of Michigan that is tied to patients’ electronic health record.

Participants provide blood or saliva for genetic screening and agree to be recontacted to enroll in additional research studies.

Rogel researchers searched the database for participants whose genetic data suggests they may have a DPYD variant, flagging 3,583 suspected carriers.

Because the participants had undergone a research-grade test, the anomaly would need to be confirmed through a more rigorous clinical test.

The team set up an alert system to notify when those patients were about to be prescribed fluorouracil or capecitabine.

When an alert came, the study team reached out to the oncologist to confirm the treatment plan and ask patients to consider clinical DPYD testing.

“We got a ping on the very first day,” Hertz said.

That patient underwent DPYD testing and was confirmed to be at high risk of toxicity

Their oncologist initiated 5-fluorouracil at half the standard dose, which was well-tolerated and eventually escalated to three-quarters the standard dose.

In two years, the system triggered 57 notifications. 

“We want all clinicians to order testing because we think evidence supports this. The Michigan Genomics Initiative is a novel use of existing genetic data at U-M. We know these patients exist. This was a straightforward way to identify potential carriers and intervene,” Hertz said.

Hertz is the medical adviser for Advocates for Universal DPD/DPYD Testing, a non-profit organization that seeks to expand pretreatment DPYD testing.

The group includes family members of people with DPYD variants who died because of toxic side effects. Hertz’s role is unpaid. Hertz also co-authored a paper urging the U.S. Food and Drug Administration to recommend DPYD testing for patients before receiving fluoropyrimidine chemotherapy.

“There are examples where pharmacogenomics has been rapidly taken up into clinical practice, but it’s always required a decision from the FDA or clinical guidelines agencies,” Hertz said.

“If there’s a law or guideline, that will change practice. Otherwise, we have to convince one clinician at a time, one patient at a time. It’s going to be a long process.”

European clinical care guidelines and the European Medicines Agency recommend DPYD testing before beginning fluoropyrimidine chemotherapy.

At the Rogel Cancer Center, leaders in the oncology clinics that use these chemotherapies embrace routine DPYD testing.

Hertz said the Michigan Genomics Institute monitoring system is an example that other research institutions can implement until DPYD testing is required.

The U-M team continues to monitor Michigan Genomics Initiative participants for potential DPYD testing.

They are also beginning to monitor for a marker linked to toxicity from the chemotherapy irinotecan.

Additional authors: Amy L. Pasternak, Robinson Seda, Joseph Lipa, Rachel L. McDevitt, Oxana V. Crysler, Paul L. Swiecicki, Bryan J. Schneider, Brett Vanderwerff, N. Lynn Henry, John C. Krauss, Vaibhav Sahai

Funding for this work is from Precision Health at the University of Michigan

Paper cited: “Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository,” Clinical Pharmacology & Therapeutics. DOI: 10.1002/cpt.2936

More Articles About: Cancer (Oncology) Cancer and Genetics Cancer Treatment Chemotherapy All Research Topics
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories white coats hanging and one swinging off hanger with purple haze over them and sunshine peeking through
Health Lab
Who feels ready for residency?
Helen Morgan, M.D., of Michigan Medicine, authored a study that surveyed obstetric and gynecology residents to determine who feels prepared for the transition from medical school to residency.
close up photo of yellow pills lined up on a bright blue matt
Health Lab
New drug candidate blocks resistance to cancer therapies
A team of researchers at the University of Michigan Health Rogel Cancer Center has designed a molecule that impairs signaling mediated by two key drivers of cancer therapy resistance.
two women, one older one younger, looking concerned listening to a provider across from them with back to camera
Health Lab
Many breast cancer survivors don't receive genetic testing, despite being eligible
As cancer treatment and survivorship care relies more on understanding the genetic make up of an individual’s tumor, a study from the University of Michigan Health Rogel Cancer Center finds that many breast cancer survivors who meet criteria for genetic counseling and testing are not receiving it.
rat in blue with yellow bright brain with blue abstract background
Health Lab
Diabetes and weight loss drugs could be enhanced, shows study in mice
A network of proteins found in the central nervous system could be harnessed to increase the effectiveness, and reduce the side effects, of diabetes and weight-loss drugs such as Ozempic and Mounjaro, according to research from the University of Michigan Life Sciences Institute. 
doctor with patient talking
Health Lab
Considering the patient’s perspective in inducible laryngeal obstruction care
Exploring the main topic of concern patients have when it comes to the results of their treatment for inducible laryngeal obstruction can help to increase effective treatment methods.
measuring band around cartoon person waist with tie and red arrow pointing high baby blue background
Health Lab
How a gene for obesity affects the brain
How a gene for obesity affects the brain: The discovery could lead to new treatments for metabolic diseases with fewer side effects